Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 20 | 2025 | 1081 | 2.630 |
Why?
|
| Lung Transplantation | 10 | 2024 | 335 | 1.620 |
Why?
|
| Heart Failure | 16 | 2025 | 2393 | 1.500 |
Why?
|
| Extracorporeal Membrane Oxygenation | 10 | 2022 | 655 | 1.420 |
Why?
|
| Heart Transplantation | 7 | 2024 | 877 | 1.320 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2024 | 197 | 0.870 |
Why?
|
| Catheterization, Central Venous | 2 | 2012 | 139 | 0.660 |
Why?
|
| Hepatitis C | 2 | 2017 | 386 | 0.650 |
Why?
|
| Device Removal | 1 | 2020 | 227 | 0.580 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2024 | 185 | 0.550 |
Why?
|
| Uridine Monophosphate | 1 | 2017 | 8 | 0.550 |
Why?
|
| Fluorenes | 1 | 2017 | 8 | 0.550 |
Why?
|
| Benzimidazoles | 1 | 2017 | 132 | 0.510 |
Why?
|
| Hepacivirus | 1 | 2017 | 272 | 0.470 |
Why?
|
| Tissue and Organ Procurement | 3 | 2015 | 246 | 0.460 |
Why?
|
| Preoperative Care | 1 | 2017 | 368 | 0.460 |
Why?
|
| Shock, Cardiogenic | 3 | 2021 | 178 | 0.450 |
Why?
|
| Resource Allocation | 1 | 2014 | 53 | 0.430 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2024 | 78 | 0.430 |
Why?
|
| Tissue Donors | 6 | 2020 | 504 | 0.410 |
Why?
|
| Polytetrafluoroethylene | 2 | 2019 | 67 | 0.390 |
Why?
|
| Middle Aged | 28 | 2025 | 29003 | 0.390 |
Why?
|
| Upper Extremity Deep Vein Thrombosis | 1 | 2012 | 3 | 0.390 |
Why?
|
| Takayasu Arteritis | 1 | 2012 | 14 | 0.370 |
Why?
|
| Peritoneal Cavity | 1 | 2011 | 20 | 0.360 |
Why?
|
| Anastomotic Leak | 1 | 2012 | 33 | 0.360 |
Why?
|
| Antiviral Agents | 1 | 2017 | 822 | 0.360 |
Why?
|
| Reoperation | 3 | 2024 | 853 | 0.360 |
Why?
|
| Lung Diseases | 2 | 2019 | 408 | 0.360 |
Why?
|
| Embolism | 1 | 2011 | 46 | 0.350 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 167 | 0.350 |
Why?
|
| Ventricular Function, Right | 1 | 2012 | 120 | 0.350 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2011 | 79 | 0.340 |
Why?
|
| Retrospective Studies | 21 | 2024 | 17424 | 0.340 |
Why?
|
| Humans | 52 | 2025 | 132132 | 0.310 |
Why?
|
| Thrombosis | 3 | 2022 | 524 | 0.310 |
Why?
|
| Heart Atria | 1 | 2011 | 340 | 0.300 |
Why?
|
| Adult | 21 | 2025 | 31585 | 0.300 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 551 | 0.290 |
Why?
|
| Female | 31 | 2025 | 70725 | 0.280 |
Why?
|
| Male | 31 | 2025 | 64985 | 0.270 |
Why?
|
| Survival Rate | 5 | 2019 | 2194 | 0.260 |
Why?
|
| Aorta, Thoracic | 1 | 2012 | 540 | 0.260 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2021 | 377 | 0.260 |
Why?
|
| Vascular Surgical Procedures | 1 | 2012 | 553 | 0.250 |
Why?
|
| Ischemia | 2 | 2024 | 370 | 0.250 |
Why?
|
| Staphylococcal Infections | 1 | 2011 | 569 | 0.250 |
Why?
|
| Follow-Up Studies | 6 | 2024 | 5419 | 0.250 |
Why?
|
| Pulmonary Artery | 2 | 2024 | 457 | 0.240 |
Why?
|
| Endostatins | 1 | 2025 | 8 | 0.230 |
Why?
|
| Treatment Outcome | 14 | 2024 | 13034 | 0.230 |
Why?
|
| Ohio | 3 | 2014 | 85 | 0.230 |
Why?
|
| Vascular Resistance | 2 | 2024 | 196 | 0.230 |
Why?
|
| Graft Rejection | 2 | 2019 | 559 | 0.230 |
Why?
|
| Lung | 4 | 2024 | 1559 | 0.230 |
Why?
|
| Cystatin C | 1 | 2025 | 74 | 0.220 |
Why?
|
| Delirium | 1 | 2025 | 61 | 0.220 |
Why?
|
| Aged | 14 | 2025 | 21442 | 0.210 |
Why?
|
| Cystic Fibrosis | 2 | 2019 | 264 | 0.200 |
Why?
|
| Heparin | 3 | 2013 | 212 | 0.200 |
Why?
|
| Prosthesis Implantation | 1 | 2024 | 156 | 0.200 |
Why?
|
| Subclavian Vein | 2 | 2012 | 21 | 0.190 |
Why?
|
| Catheterization | 3 | 2012 | 241 | 0.190 |
Why?
|
| Anticoagulants | 4 | 2022 | 609 | 0.190 |
Why?
|
| Mitral Valve | 1 | 2024 | 270 | 0.190 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2023 | 107 | 0.180 |
Why?
|
| Postoperative Complications | 5 | 2025 | 3143 | 0.180 |
Why?
|
| Hyponatremia | 1 | 2022 | 74 | 0.180 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2024 | 461 | 0.170 |
Why?
|
| Machine Learning | 1 | 2024 | 346 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 6 | 2005 | 729 | 0.170 |
Why?
|
| Tracheostomy | 2 | 2023 | 204 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2025 | 2172 | 0.160 |
Why?
|
| Renal Replacement Therapy | 1 | 2021 | 158 | 0.150 |
Why?
|
| Mitochondria | 1 | 2024 | 747 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2024 | 1176 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 3 | 2005 | 40 | 0.150 |
Why?
|
| Hemorrhage | 2 | 2019 | 519 | 0.140 |
Why?
|
| Medical Overuse | 1 | 2018 | 26 | 0.140 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 256 | 0.140 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 116 | 0.140 |
Why?
|
| Kidney | 1 | 2025 | 1331 | 0.140 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 149 | 0.140 |
Why?
|
| Acute Lung Injury | 1 | 2018 | 68 | 0.140 |
Why?
|
| Allografts | 1 | 2018 | 195 | 0.140 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2019 | 175 | 0.140 |
Why?
|
| Incidence | 4 | 2024 | 3381 | 0.140 |
Why?
|
| Sofosbuvir | 1 | 2017 | 21 | 0.140 |
Why?
|
| Acute Kidney Injury | 1 | 2025 | 672 | 0.140 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 233 | 0.130 |
Why?
|
| Time Factors | 6 | 2024 | 6454 | 0.130 |
Why?
|
| Echocardiography | 3 | 2011 | 1129 | 0.130 |
Why?
|
| Graft Survival | 3 | 2020 | 474 | 0.120 |
Why?
|
| Blood Transfusion | 1 | 2018 | 291 | 0.120 |
Why?
|
| Thiophenes | 4 | 2000 | 67 | 0.120 |
Why?
|
| Phenylalanine | 4 | 2000 | 123 | 0.120 |
Why?
|
| Stroke | 1 | 2024 | 1085 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 758 | 0.120 |
Why?
|
| Equipment Design | 2 | 2021 | 614 | 0.120 |
Why?
|
| Metalloendopeptidases | 3 | 2000 | 100 | 0.110 |
Why?
|
| Pulmonary Heart Disease | 1 | 2014 | 4 | 0.110 |
Why?
|
| Bacteria | 1 | 2018 | 524 | 0.110 |
Why?
|
| Prognosis | 4 | 2021 | 5014 | 0.110 |
Why?
|
| Compartment Syndromes | 1 | 2014 | 32 | 0.110 |
Why?
|
| Fatal Outcome | 2 | 2013 | 370 | 0.110 |
Why?
|
| Death | 1 | 2015 | 79 | 0.110 |
Why?
|
| Extremities | 1 | 2014 | 84 | 0.100 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2014 | 153 | 0.100 |
Why?
|
| Young Adult | 5 | 2019 | 9961 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1132 | 0.100 |
Why?
|
| Brain | 1 | 2025 | 3183 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2012 | 104 | 0.100 |
Why?
|
| Axillary Artery | 1 | 2012 | 30 | 0.100 |
Why?
|
| Donor Selection | 1 | 2013 | 58 | 0.090 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2012 | 41 | 0.090 |
Why?
|
| Drug Overdose | 1 | 2013 | 74 | 0.090 |
Why?
|
| Jugular Veins | 1 | 2012 | 75 | 0.090 |
Why?
|
| Aneurysm, Ruptured | 1 | 2011 | 35 | 0.090 |
Why?
|
| Coronary Aneurysm | 1 | 2011 | 33 | 0.090 |
Why?
|
| Matrix Metalloproteinase 2 | 5 | 2005 | 90 | 0.090 |
Why?
|
| Catheters, Indwelling | 1 | 2012 | 157 | 0.090 |
Why?
|
| Equipment Failure | 1 | 2011 | 137 | 0.090 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2011 | 52 | 0.090 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2012 | 134 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 1460 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2012 | 367 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2557 | 0.080 |
Why?
|
| Adenocarcinoma | 3 | 2005 | 1016 | 0.080 |
Why?
|
| End Stage Liver Disease | 1 | 2012 | 191 | 0.080 |
Why?
|
| Liver Function Tests | 1 | 2010 | 102 | 0.080 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2012 | 277 | 0.080 |
Why?
|
| Fibroma | 1 | 2010 | 31 | 0.080 |
Why?
|
| Risk Factors | 5 | 2024 | 10949 | 0.080 |
Why?
|
| Hospitals | 2 | 2023 | 438 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 245 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2012 | 189 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2024 | 3739 | 0.080 |
Why?
|
| Gelatinases | 2 | 1999 | 16 | 0.080 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2012 | 386 | 0.080 |
Why?
|
| Heart Neoplasms | 1 | 2010 | 104 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 1952 | 0.070 |
Why?
|
| Protease Inhibitors | 2 | 1999 | 97 | 0.070 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2012 | 516 | 0.070 |
Why?
|
| Transfection | 3 | 2005 | 996 | 0.070 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 460 | 0.070 |
Why?
|
| Stroke Volume | 1 | 2010 | 541 | 0.070 |
Why?
|
| Mortality | 2 | 2019 | 268 | 0.070 |
Why?
|
| DNA, Antisense | 1 | 2005 | 8 | 0.060 |
Why?
|
| Preoperative Period | 1 | 2025 | 92 | 0.060 |
Why?
|
| Atrophy | 1 | 2025 | 252 | 0.050 |
Why?
|
| Neoplasm Transplantation | 5 | 2005 | 382 | 0.050 |
Why?
|
| Heart Arrest, Induced | 1 | 2024 | 77 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2024 | 124 | 0.050 |
Why?
|
| Organ Size | 1 | 2025 | 449 | 0.050 |
Why?
|
| Liver Transplantation | 1 | 2012 | 1103 | 0.050 |
Why?
|
| Gene Expression | 3 | 2005 | 1558 | 0.050 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2000 | 17 | 0.050 |
Why?
|
| Mice, Nude | 5 | 2005 | 752 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2010 | 898 | 0.050 |
Why?
|
| Hypothermia, Induced | 1 | 2024 | 170 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2025 | 6571 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2010 | 1047 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2019 | 1234 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 5 | 2002 | 1045 | 0.050 |
Why?
|
| Neuroimaging | 1 | 2025 | 377 | 0.050 |
Why?
|
| Immunohistochemistry | 4 | 2010 | 1694 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2002 | 257 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1356 | 0.040 |
Why?
|
| Mean Platelet Volume | 1 | 2019 | 4 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2024 | 1230 | 0.040 |
Why?
|
| I-kappa B Proteins | 1 | 1999 | 39 | 0.040 |
Why?
|
| Macrophages, Peritoneal | 1 | 1999 | 39 | 0.040 |
Why?
|
| Polymyxins | 1 | 2019 | 15 | 0.040 |
Why?
|
| Collagenases | 1 | 1999 | 17 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2002 | 719 | 0.040 |
Why?
|
| Shock, Hemorrhagic | 1 | 1999 | 55 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2022 | 1573 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1057 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2022 | 791 | 0.030 |
Why?
|
| Shock, Septic | 1 | 1999 | 154 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2018 | 335 | 0.030 |
Why?
|
| NF-kappa B | 1 | 1999 | 454 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2024 | 3093 | 0.030 |
Why?
|
| Blotting, Western | 3 | 2005 | 1077 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 360 | 0.030 |
Why?
|
| Biomarkers | 1 | 2025 | 3405 | 0.030 |
Why?
|
| Respiration, Artificial | 1 | 2018 | 504 | 0.030 |
Why?
|
| Organ Preservation | 1 | 2015 | 53 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 1581 | 0.030 |
Why?
|
| Texas | 1 | 2022 | 3630 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1672 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 195 | 0.030 |
Why?
|
| Animals | 9 | 2012 | 34882 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2015 | 237 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2000 | 1342 | 0.020 |
Why?
|
| Reperfusion | 1 | 2012 | 26 | 0.020 |
Why?
|
| Mice | 7 | 2005 | 18507 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 3418 | 0.020 |
Why?
|
| Acute Disease | 1 | 2014 | 1160 | 0.020 |
Why?
|
| Perfusion | 1 | 2012 | 208 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 749 | 0.020 |
Why?
|
| Quality of Life | 1 | 2021 | 2161 | 0.020 |
Why?
|
| Endocardial Fibroelastosis | 1 | 2010 | 11 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2005 | 663 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2010 | 134 | 0.020 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2010 | 87 | 0.020 |
Why?
|
| Chest Pain | 1 | 2010 | 128 | 0.020 |
Why?
|
| Swine | 1 | 2012 | 1200 | 0.020 |
Why?
|
| Dyspnea | 1 | 2010 | 159 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2010 | 262 | 0.020 |
Why?
|
| Oxygen | 1 | 2012 | 572 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 20564 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2010 | 485 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 4688 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2000 | 1046 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2917 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2010 | 1014 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2002 | 2674 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 459 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 1170 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 124 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2002 | 76 | 0.010 |
Why?
|
| Pancreas | 1 | 2002 | 222 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 2000 | 60 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 743 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2000 | 277 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 235 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2000 | 83 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2000 | 217 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2000 | 435 | 0.010 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 1999 | 3 | 0.010 |
Why?
|
| Survival | 1 | 1999 | 18 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 1999 | 32 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1999 | 157 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 708 | 0.010 |
Why?
|
| Cytosol | 1 | 1999 | 144 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2000 | 822 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 1999 | 137 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1999 | 615 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2005 | 2508 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 3681 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 1999 | 306 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1999 | 587 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 664 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1999 | 1222 | 0.010 |
Why?
|
| Body Weight | 1 | 2000 | 994 | 0.010 |
Why?
|
| Apoptosis | 1 | 2002 | 1892 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1422 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1999 | 3036 | 0.010 |
Why?
|
| Rats | 1 | 1999 | 3611 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2002 | 1381 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 1999 | 1977 | 0.010 |
Why?
|
| Signal Transduction | 1 | 1999 | 4703 | 0.000 |
Why?
|